Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 29 min 28 sec ago

Sproutly Enters into Non-Binding Letters of Intent to Acquire Infusion Biosciences Canada

4 hours 29 min ago
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sproutly Inc.: NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Sproutly Inc. (“Sproutly” or the “Company”) is pleased to announce that it has entered into non-binding letters of intent (the “Letters of Intent”) to acquire: 1) Infusion Biosciences Canada Inc., a biotech company possessing the rights to Infusion Biosciences Inc.’s (“Infusion Biosciences”) APP Technology (defined below) for specific jurisdictions; and 2) SSM Partners In

Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement

6 hours 29 min ago
RICHMOND, British Columbia & GUILFORD, Conn.--(BUSINESS WIRE)--$BIOAF #BBB--Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement

Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology

7 hours 29 min ago
TORONTO--(BUSINESS WIRE)--Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology

Dr. Daniel Siegel, Professor of Dermatology and former President of the American Academy of Dermatology joins MedX’s Medical Advisory Board

Wed, 23/05/2018 - 08:02
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that Dr. Daniel Siegel, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined its Medical Advisory Board. “Daniel’s academic and practical business experience is impressive, including his expertise as a health policy and reimbursement specialist. His many skills will help MedX develop a strong launch platform for t

Covalon Provides Further Information Regarding Estimated $100 Million Competitive Contract Awards

Tue, 22/05/2018 - 09:01
MISSISSAUGA, Ontario--(BUSINESS WIRE)--#award--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV; OTCQX:CVALF), an advanced medical technologies company, is pleased to provide further information on the previously-announced series of competitive contracts in the Middle East won by the Company with an estimated sales value of $100 million over a three-year period. Covalon has been informed that it has been awarded all the Vascular Access dressing categories that were tendered under the Ex

Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer

Mon, 21/05/2018 - 09:00
RICHMOND, British Columbia & GUILFORD, Conn. & SHANGHAI--(BUSINESS WIRE)--$BIOAF #BBB--Bioasis & WuXi Biologics announce initial strategic collaboration for the development and manufacturing of xB3-001.

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

Mon, 21/05/2018 - 07:00
CORK, Ireland--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA.

Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement

Thu, 17/05/2018 - 17:00
RICHMOND, British Columbia & GUILFORD, Conn.--(BUSINESS WIRE)--$BIOAF #BBB--Bioasis Technologies Inc. is pleased to announce that it has completed a first tranche of its previously announced private placement of units.

OBIO Announces 12 New OBIO CAAP® Companies for 2018

Thu, 17/05/2018 - 15:00
TORONTO--(BUSINESS WIRE)--#healthscience--OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 12 high-potential health science companies in this year’s cohort.

Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings

Thu, 17/05/2018 - 13:00
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of 14 Takeda Oncology-sponsored presentations at two upcoming medical meetings: the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 in Chicago and the 23rd Congress of the European Hematology Association (EHA), June 14-17 in Stockholm. This year’s presentations will underscore Takeda’s unwavering pursuit to ad

Acerus Announces Buyout of All Obligations under the Mattern License Agreement

Thu, 17/05/2018 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today reported that it has entered into an agreement with Mattern Pharma AG (“Mattern”) to buy out all of its obligations (the “Buyout”) under the Amended and Restated Intellectual Property Rights and Product Development Agreement, dated December 21, 2013 (as amended) (“License Agreement”), including all of its future royalty payment obligations. Under the License Agreement, Acerus owed royalties

Interest in Agri-Food Innovation Leads to MOU Between Ag-West Bio, and World Trade Centers in Saskatoon and Harbin, China

Wed, 16/05/2018 - 16:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Interest in agri-food innovation leads to MOU between Ag-West Bio, and World Trade Centers in Saskatoon and Harbin, China

Late-Stage ACMPR Applicant, OneLeaf Cannabis Corp., Enters “Active Review” with Health Canada and Provides Update on Construction of 48,200 Sq. Ft. Cannabis Production Facility Near Regina, SK.

Wed, 16/05/2018 - 11:00
REGINA, Saskatchewan--(BUSINESS WIRE)--#ACMPR--OneLeaf Cannabis Corp. - a late stage ACMPR applicant - enters 'Active Review' with Health Canada and provides update on facility construction.

NAMSA Recognized as Leading Medical Device CRO for Second Consecutive Year by Life Science Leader

Wed, 16/05/2018 - 10:00
TOLEDO, Ohio--(BUSINESS WIRE)--#CRO--NAMSA announces recognition for excellence in clinical research for second consecutive year as winner of 2018 “CRO Leadership Award”

Turnstone Biologics Announces U.S. FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers

Wed, 16/05/2018 - 08:00
NEW YORK & OTTAWA, Ontario--(BUSINESS WIRE)--Turnstone Biologics Announces U.S. FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers

Cerveau Technologies, Inc. Signs Research Agreement with Tokyo Metropolitan Institute of Gerontology, Japan

Tue, 15/05/2018 - 11:00
BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced an agreement with the Tokyo Metropolitan Institute of Gerontology in Japan to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodeg

Acerus Reports First Quarter 2018 Financial Results

Tue, 15/05/2018 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation : Product revenues increased 60% to $1.6 million versus $1.0 million in the same prior year period NATESTO® received public reimbursement listing in Quebec (40% of Canadian testosterone prescription market) In-licensed two additional products (URIVARX®, STENDRA®) to further leverage Acerus’ men and women’s health platform Launched URIVARX® for overactive bladder New President and Chief Executive Officer appointed Acerus Pharmaceutical

Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

Mon, 14/05/2018 - 18:00
VANCOUVER, British Columbia & TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced today that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement. “With a successful track record and our first bispecific antibody incorporating the Azymetric and EFECT technology havi

Commemorating 50 Years of Canadian Animal Heroes

Mon, 14/05/2018 - 12:00
TORONTO--(BUSINESS WIRE)--Animals have the power to continuously amaze us, particularly when it comes to their unique means of communication with humans through various signals and behaviours. Animals are often capable of understanding us and incredibly, many can instinctually alert their humans to impending danger. Time and time again, this proves their deep intelligence, loyalty and connection to those they love. Today, the team at Purina is pleased to mark the 50th anniversary of its renowne

Lattice Biologics Ltd. Announces Management Cease Trading Order is Revoked

Mon, 14/05/2018 - 10:00
BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces the Company has successfully filed all necessary reporting documents and the preceding MCTO was revoked as of May 1, 2018. For the past few months, the Company provided default status reports in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis an

Pages